Biotron (OTCPK:BITR.F) - Stock Price, News & Analysis

BITR.F Stock Overview

A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. More details

BITR.F fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Earnings have declined by 2.6% per year over past 5 years

Has less than 1 year of cash runway

Negative shareholders equity

Shares are highly illiquid

+ 2 more risks

Biotron Limited Competitors

HCW Biologics

NasdaqGM:HCWB

US$35.8m

Apollomics

NasdaqCM:APLM

US$16.5m

America Great Health

OTCPK:AAGH

US$10.6m

Eagle Pharmaceuticals

OTCPK:EGRX

US$8.5m

Price History & Performance

Summary of all time highs, changes and price drops for Biotron
Historical stock prices
Current Share Price	AU$0.013
52 Week High	AU$0.072
52 Week Low	AU$0.011
Beta	-0.64
11 Month Change	-19.23%
3 Month Change	n/a
1 Year Change	-79.87%
33 Year Change	-48.05%
5 Year Change	-71.55%
Change since IPO	-91.06%

Recent updates

Shareholder Returns

	BITR.F	US Biotechs	US Market
7D	0%	-3.7%	0.3%
1Y	-79.9%	15.2%	31.1%

Return vs Industry: BITR.F underperformed the US Biotechs industry which returned 14.6% over the past year.

Return vs Market: BITR.F underperformed the US Market which returned 30.3% over the past year.

Price Volatility

Is BITR.F's price volatile compared to industry and market?
BITR.F volatility
BITR.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: BITR.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BITR.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	Michelle Miller	www.biotron.com.au

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is based in Sydney, Australia.

Biotron Limited Fundamentals Summary

How do Biotron's earnings and revenue compare to its market cap?
BITR.F fundamental statistics
Market cap	US$11.16m
Earnings (TTM)	-US$2.24m
Revenue (TTM)	US$1.07m

10.4x

P/S Ratio

-5.0x

P/E Ratio

Is BITR.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BITR.F income statement (TTM)
Revenue	AU$1.65m
Cost of Revenue	AU$0
Gross Profit	AU$1.65m
Other Expenses	AU$5.08m
Earnings	-AU$3.44m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0038
Gross Margin	100.00%
Net Profit Margin	-208.89%
Debt/Equity Ratio	0%

How did BITR.F perform over the long term?

See historical performance and comparison

Biotron OTCPK:BITR.F Stock Report